Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
المؤلفون المشاركون
Tsang, Erica S.
Loree, Jonathan M.
Davies, Janine M.
Gill, Sharlene
Liu, David
Ho, Stephen
Renouf, Daniel J.
Lim, Howard J.
Kennecke, Hagen F.
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-11-23
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background.
Yttrium-90 (Y-90) can be an effective liver-directed therapy for patients with metastatic neuroendocrine tumors (NETs), but population-based data are limited.
We characterized the use of Y-90 in NET patients and identified factors associated with response.
Methods.
We identified 49 patients with metastatic liver-dominant NETs across BC Cancer’s six regional centres who received Y-90 between June 2011 and January 2017 in British Columbia, Canada.
Baseline characteristics, radiographic responses, and outcomes were summarized.
Results.
Of the 49 patients who received Y-90, the median age was 56 years (range 21–78), 49% were male, and 94% had an ECOG performance status of 0–1.
The primary location of the NET included pancreas (31%), small bowel (41%), large bowel (6%), unknown (14%), and others (12%).
69% of these patients had liver metastases alone, and tumors were graded as G1 (61%), G2 (25%), G3 (2%), and unknown (12%).
Prior therapies included surgery (63%), local ablative therapy (25%), somatostatin analogue (69%), and systemic therapy (35%).
The median Y-90 dose was 2.2 GBq (range 0.8–3.6), as SIR-spheres (69%) or TheraSpheres (29%).
Median time to Y-90 from diagnosis of metastases measured 1.54 years.
88% received segmental Y-90, with 1 (69%), 2 (29%), and 3 (2%) treatments.
Y-90 resulted in partial response (53%), stable disease (33%), and progressive disease (12%).
Y-90 was well-tolerated, with infrequent grade 3-4 biochemical toxicities (2%) and grade 3 abdominal pain (6%).
Longer overall survival (OS) was associated with resection of primary tumor, well-differentiated histology, and low Ki-67.
Median OS was 27.2 months (95% CI 8.0–46.5).Conclusions.
In our population-based cohort, Y-90 was well-tolerated in patients with metastatic liver-dominant NETs.
Prior surgical resection was an important predictor of OS.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tsang, Erica S.& Loree, Jonathan M.& Davies, Janine M.& Gill, Sharlene& Liu, David& Ho, Stephen…[et al.]. 2020. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1139014
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tsang, Erica S.…[et al.]. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1139014
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tsang, Erica S.& Loree, Jonathan M.& Davies, Janine M.& Gill, Sharlene& Liu, David& Ho, Stephen…[et al.]. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1139014
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1139014
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر